Posts tagged Local Coverage Determinations.
Blogs
2 minute read
GenomeDx Biosciences Corp., which markets a genomic test (Decipher®) intended to assess the aggressiveness of prostate cancer, has agreed to pay $1.99 million to the U.S. Department of Justice to resolve allegations that it violated the False Claims Act (31 U.S.C. §§ 3729 et seq.)(“FCA”) by submitting claims to Medicare for tests conducted to evaluate treatment options for men after prostate surgery.
The government and a whistleblower alleged that between September 2015 and June 2017, GenomeDx knowingly submitted Medicare reimbursement claims for the Decipher® test ...
Blog Editors
Recent Updates
- Warning - Transaction Delays Expected. State Notice Requirements Ahead for Health Care M&A!
- New York Aims to Bolster Hospital Cybersecurity with Imminent Release of Proposed Regulations
- Sharing Scientific Information with HCPs on Unapproved Uses of Medical Products: Dos and Don’ts Under FDA’s New Draft Guidance
- Abortion Rights to Be Codified in Ohio State Constitution
- The Guiding an Improved Dementia Experience (“GUIDE”) Model